Additionally, the ERBB2-CAR-T cell infusions for NSCLC patients showed 23.5% (4/17) SD for 12 weeks to 14 months; 17.7% (3/17) patients underwent surgical resection of their residual tumors, and one of these patients showed ≥ 90% tumor necrosis (ClinicalTrials.gov identifier: NCT00902044) [153]. The gene discussed is ERBB2; the disease is neoplasm.